To the Editor Dr Ranieri and colleagues1 found that intravenous interferon (IFN) β-1a administered for 6 days, compared with placebo, did not result in significant improvement in a composite score that included death and ventilator-free days over a total of 28 days in patients with acute respiratory distress syndrome (ARDS). Some important issues remain to be discussed.
Zhou X, Tang G. Intravenous Interferon β-1a for Severe ARDS. JAMA. 2020;324(5):515. doi:10.1001/jama.2020.7980
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: